Related Experiment Video
Updated: Mar 16, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
Cardiovascular Prevention in Obese Patients
Manuel F Landecho, Rafael Moncada, Víctor Valentí
1Department of Endocrinology & Nutrition, Clínica Universitaria de Navarra, Avda. Pío XII, 36, 31008- Pamplona, Spain.
Current Pharmaceutical Design
|August 24, 2016
Summary
Increased body mass index (BMI) is a significant risk factor for cardiovascular disease (CVD) and other non-communicable diseases. Addressing obesity through various strategies is crucial for public health and individual well-being.
Area of Science:
- Cardiology
- Endocrinology
- Public Health
Background:
- Increased body mass index (BMI) is a major risk factor for non-communicable diseases (NCDs), including cardiovascular disease (CVD), diabetes, and cancer.
- Obesity has been recognized as an independent risk factor for CVD since 1995, with risks escalating with higher BMI.
- Obesity contributes to metabolic syndrome, a cluster of conditions significantly increasing CVD risk.
Purpose of the Study:
- To review the association between excess body fat and CVD.
- To examine controversies like the obesity paradox and metabolically healthy obesity.
- To explore beneficial effects of weight loss and current obesity treatment strategies for cardiovascular risk reduction.
Main Methods:
- Literature review focusing on the link between obesity and CVD.
- Analysis of studies on the obesity paradox and metabolically healthy obesity.
- Evaluation of weight loss benefits and treatment modalities including lifestyle, drugs, and surgery.
Main Results:
- Dysfunctional fat accumulation is strongly linked to cardiovascular disease (CVD).
- The concept of "metabolically healthy obesity" and the "obesity paradox" present complex, debated aspects of the condition.
- Weight loss interventions demonstrably reduce cardiovascular morbidity and mortality.
Conclusions:
- Obesity is a complex, heterogeneous disease requiring personalized treatment plans.
- Weight loss, achievable through various methods, improves health outcomes and quality of life.
- Tailored, long-term therapeutic strategies are essential for managing obesity and its cardiovascular risks.
Related Concept Videos
01:21Drug Dosing: Obese Patients
329
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
329
01:26Coronary Artery Disease IV: Preventive Measures
798
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
798
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
343
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
343
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
267
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
267
01:26Atherosclerosis III: Management
562
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
562
01:20Exercise and Cardiovascular Response
4.9K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
4.9K